Emerging Approaches to Management of Left Ventricular Outflow Obstruction Risk in Transcatheter Mitral Valve Replacement.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
24 04 2023
Historique:
received: 22 11 2022
revised: 09 01 2023
accepted: 17 01 2023
medline: 28 4 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

An increasing number of patients with mitral valve disease are high risk for surgery and in need of less invasive treatments including transcatheter mitral valve replacement (TMVR). Left ventricular outflow tract (LVOT) obstruction is a predictor of poor outcome after TMVR, and its risk can be accurately predicted using cardiac computed tomography analysis. Novel treatment strategies that have shown efficacy in reducing risk of LVOT obstruction after TMVR include pre-emptive alcohol septal ablation, radiofrequency ablation, and anterior leaflet electrosurgical laceration. This review describes recent advances in the management of LVOT obstruction risk after TMVR, provides a new management algorithm, and explores forthcoming studies that will further advance the field.

Identifiants

pubmed: 37100552
pii: S1936-8798(23)00406-5
doi: 10.1016/j.jcin.2023.01.357
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

885-895

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Mahoney has served as a consultant for Edwards Lifesciences and Medtronic. Dr Killu has served as a consultant for Boston Scientific; and has received honoraria from Biosense Webster. Dr. Guerrero has received institutional research grant support from Edwards Lifesciences; and has served as consultant for Abbott Structural Heart and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Mackram F Eleid (MF)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/EleidMack.

Jeremy D Collins (JD)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Paul Mahoney (P)

Sentara Heart Hospital, Norfolk, Virginia, USA.

Eric E Williamson (EE)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Brian K Whisenant (BK)

Division of Cardiology, Intermountain Heart Institute, Salt Lake City, Utah, USA.

Charanjit S Rihal (CS)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Mayra E Guerrero (ME)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/MayraGuerreroMD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH